Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: data from an international registry

Background and aims - Homozygous familial hypercholesterolemia (hoFH) may cause life-threatening atherosclerotic cardiovascular disease in childhood. Lipoprotein apheresis (LA) is considered a pivotal treatment option, but data on its efficacy, safety and optimal performance are limited. We therefor...

Full description

Saved in:
Bibliographic Details
Main Authors: Luirink, Ilse K. (Author) , Hutten, Barbara A. (Author) , Greber-Platzer, Susanne (Author) , Kolovou, Genovefa D. (Author) , Dann, Eldad J. (Author) , de Ferranti, Sarah D. (Author) , Taylan, Christina (Author) , Bruckert, Eric (Author) , Saheb, Samir (Author) , Oh, Jun (Author) , Driemeyer, Joenna (Author) , Farnier, Michel (Author) , Pape, Lars (Author) , Schmitt, Claus P. (Author) , Novoa, Francisco J. (Author) , Maeser, Martin (Author) , Masana, Luis (Author) , Shahrani, Awad (Author) , Wiegman, Albert (Author) , Groothoff, Jaap W. (Author)
Format: Article (Journal)
Language:English
Published: 18 February 2020
In: Atherosclerosis
Year: 2020, Volume: 299, Pages: 24-31
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2020.01.031
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.atherosclerosis.2020.01.031
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0021915020300733
Get full text
Author Notes:Ilse K. Luirink, Barbara A. Hutten, Susanne Greber-Platzer, Genovefa D. Kolovou, Eldad J. Dann, Sarah D. de Ferranti, Christina Taylan, Eric Bruckert, Samir Saheb, Jun Oh, Joenna Driemeyer, Michel Farnier, Lars Pape, Claus P. Schmitt, Francisco J. Novoa, Martin Maeser, Luis Masana, Awad Shahrani, Albert Wiegman, Jaap W. Groothoff

MARC

LEADER 00000caa a2200000 c 4500
001 1698461380
003 DE-627
005 20240406193202.0
007 cr uuu---uuuuu
008 200518s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.atherosclerosis.2020.01.031  |2 doi 
035 |a (DE-627)1698461380 
035 |a (DE-599)KXP1698461380 
035 |a (OCoLC)1341325418 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Luirink, Ilse K.  |e VerfasserIn  |0 (DE-588)1186723238  |0 (DE-627)1665992670  |4 aut 
245 1 0 |a Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia  |b data from an international registry  |c Ilse K. Luirink, Barbara A. Hutten, Susanne Greber-Platzer, Genovefa D. Kolovou, Eldad J. Dann, Sarah D. de Ferranti, Christina Taylan, Eric Bruckert, Samir Saheb, Jun Oh, Joenna Driemeyer, Michel Farnier, Lars Pape, Claus P. Schmitt, Francisco J. Novoa, Martin Maeser, Luis Masana, Awad Shahrani, Albert Wiegman, Jaap W. Groothoff 
264 1 |c 18 February 2020 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 18.05.2020 
520 |a Background and aims - Homozygous familial hypercholesterolemia (hoFH) may cause life-threatening atherosclerotic cardiovascular disease in childhood. Lipoprotein apheresis (LA) is considered a pivotal treatment option, but data on its efficacy, safety and optimal performance are limited. We therefore established an international registry on the execution and outcomes of LA in HoFH children. Here we report LA policies and short-term outcomes. - Methods - We approached centers worldwide, involved in LA in children with hoFH for participation. We collected information on clinical and treatment characteristics on patients aged 0-19 years between November 2016 and November 2018. - Results - We included 50 children, treated at 15 sites. Median (IQR) LDL-C levels at diagnosis, on medication and on LA were 19.2 (16.2-22.1), 14.4 (10.8-16.7) mmol/L and 4.6 mmol/L, respectively. Median (IQR) time between diagnosis and start of LA was 2.8 (1.0-4.7) years. Six (12%) patients developed cardiovascular disease during that period. Most children received LA either weekly (43%) or biweekly (37%). Seven (17%) patients reached mean LDL-C levels <3.5 mmol/L, all of them treated at least weekly. Xanthomas were present in 42 (84%) patients at diagnosis and disappeared completely in 19 (45%) on LA. Side effects of LA were minor. There were significant differences in LA conduction between sites in terms of frequency, responsible medical specialities and vascular access. - Conclusions - LA is a safe treatment and may effectively lower LDL-C in children with HoFH. However, there is room for improvement with respect to time of onset and optimization of LA therapy in terms of frequency and execution. 
650 4 |a Children 
650 4 |a Familial hypercholesterolemia 
650 4 |a Homozygous 
650 4 |a Lipoprotein spheresis 
700 1 |a Hutten, Barbara A.  |e VerfasserIn  |4 aut 
700 1 |a Greber-Platzer, Susanne  |e VerfasserIn  |4 aut 
700 1 |a Kolovou, Genovefa D.  |e VerfasserIn  |4 aut 
700 1 |a Dann, Eldad J.  |e VerfasserIn  |4 aut 
700 1 |a de Ferranti, Sarah D.  |e VerfasserIn  |4 aut 
700 1 |a Taylan, Christina  |e VerfasserIn  |4 aut 
700 1 |a Bruckert, Eric  |e VerfasserIn  |4 aut 
700 1 |a Saheb, Samir  |e VerfasserIn  |4 aut 
700 1 |a Oh, Jun  |e VerfasserIn  |4 aut 
700 1 |a Driemeyer, Joenna  |e VerfasserIn  |4 aut 
700 1 |a Farnier, Michel  |e VerfasserIn  |4 aut 
700 1 |a Pape, Lars  |e VerfasserIn  |4 aut 
700 1 |a Schmitt, Claus P.  |e VerfasserIn  |0 (DE-588)1030179123  |0 (DE-627)734893620  |0 (DE-576)377990280  |4 aut 
700 1 |a Novoa, Francisco J.  |e VerfasserIn  |4 aut 
700 1 |a Maeser, Martin  |e VerfasserIn  |4 aut 
700 1 |a Masana, Luis  |e VerfasserIn  |4 aut 
700 1 |a Shahrani, Awad  |e VerfasserIn  |4 aut 
700 1 |a Wiegman, Albert  |e VerfasserIn  |4 aut 
700 1 |a Groothoff, Jaap W.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Atherosclerosis  |d Amsterdam [u.a.] : Elsevier Science, 1970  |g 299(2020), Seite 24-31  |h Online-Ressource  |w (DE-627)306654091  |w (DE-600)1499887-7  |w (DE-576)081984545  |x 1879-1484  |7 nnas  |a Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia data from an international registry 
773 1 8 |g volume:299  |g year:2020  |g pages:24-31  |g extent:8  |a Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia data from an international registry 
856 4 0 |u https://doi.org/10.1016/j.atherosclerosis.2020.01.031  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0021915020300733  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200518 
993 |a Article 
994 |a 2020 
998 |g 1030179123  |a Schmitt, Claus P.  |m 1030179123:Schmitt, Claus P.  |d 910000  |d 910500  |e 910000PS1030179123  |e 910500PS1030179123  |k 0/910000/  |k 1/910000/910500/  |p 14 
999 |a KXP-PPN1698461380  |e 3668211531 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1016/j.atherosclerosis.2020.01.031"],"eki":["1698461380"]},"recId":"1698461380","origin":[{"dateIssuedDisp":"18 February 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Ilse K. Luirink, Barbara A. Hutten, Susanne Greber-Platzer, Genovefa D. Kolovou, Eldad J. Dann, Sarah D. de Ferranti, Christina Taylan, Eric Bruckert, Samir Saheb, Jun Oh, Joenna Driemeyer, Michel Farnier, Lars Pape, Claus P. Schmitt, Francisco J. Novoa, Martin Maeser, Luis Masana, Awad Shahrani, Albert Wiegman, Jaap W. Groothoff"]},"language":["eng"],"note":["Gesehen am 18.05.2020"],"person":[{"family":"Luirink","role":"aut","display":"Luirink, Ilse K.","given":"Ilse K."},{"given":"Barbara A.","family":"Hutten","role":"aut","display":"Hutten, Barbara A."},{"given":"Susanne","role":"aut","family":"Greber-Platzer","display":"Greber-Platzer, Susanne"},{"family":"Kolovou","role":"aut","display":"Kolovou, Genovefa D.","given":"Genovefa D."},{"given":"Eldad J.","display":"Dann, Eldad J.","family":"Dann","role":"aut"},{"given":"Sarah D.","role":"aut","family":"de Ferranti","display":"de Ferranti, Sarah D."},{"given":"Christina","role":"aut","family":"Taylan","display":"Taylan, Christina"},{"role":"aut","family":"Bruckert","display":"Bruckert, Eric","given":"Eric"},{"family":"Saheb","role":"aut","display":"Saheb, Samir","given":"Samir"},{"display":"Oh, Jun","family":"Oh","role":"aut","given":"Jun"},{"given":"Joenna","display":"Driemeyer, Joenna","family":"Driemeyer","role":"aut"},{"display":"Farnier, Michel","role":"aut","family":"Farnier","given":"Michel"},{"family":"Pape","role":"aut","display":"Pape, Lars","given":"Lars"},{"given":"Claus P.","display":"Schmitt, Claus P.","role":"aut","family":"Schmitt"},{"family":"Novoa","role":"aut","display":"Novoa, Francisco J.","given":"Francisco J."},{"given":"Martin","role":"aut","family":"Maeser","display":"Maeser, Martin"},{"family":"Masana","role":"aut","display":"Masana, Luis","given":"Luis"},{"given":"Awad","display":"Shahrani, Awad","family":"Shahrani","role":"aut"},{"family":"Wiegman","role":"aut","display":"Wiegman, Albert","given":"Albert"},{"given":"Jaap W.","role":"aut","family":"Groothoff","display":"Groothoff, Jaap W."}],"relHost":[{"part":{"text":"299(2020), Seite 24-31","year":"2020","pages":"24-31","volume":"299","extent":"8"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Atherosclerosis","title":"Atherosclerosis"}],"id":{"zdb":["1499887-7"],"eki":["306654091"],"issn":["1879-1484"]},"recId":"306654091","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia data from an international registryAtherosclerosis","origin":[{"dateIssuedDisp":"[1970?]-","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science"}],"pubHistory":["Nachgewiesen 11.1970 -"],"note":["Gesehen am 14.10.2020"],"language":["eng"]}],"title":[{"title_sort":"Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia","subtitle":"data from an international registry","title":"Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia"}],"physDesc":[{"extent":"8 S."}]} 
SRT |a LUIRINKILSPRACTICEOF1820